A new competitiveness framework has revealed that the UK is losing the race for investment in pharmaceutical R&D, clinical trial delivery, and foreign direct investment due to an increasingly tough trading environment.
The new framework, from trade group the Association of the British Pharmaceutical Industry (ABPI), is entitled Creating the Conditions for Investment and Growth and has been produced in partnership with PwC. It outlines the key factors that drive international competitiveness for pharmaceuticals, ranking the UK among its peers and highlighting the country’s relative strengths and weaknesses
In addition to the 48 competitiveness indicators used to benchmark the UK’s attractiveness compared to its peers across key investment factors, the framework also presents concise summaries of the strengths and weaknesses of other countries competing for investment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK